Provectus Biopharmaceuticals reported positive preclinical results for oral PV-10, a rose bengal sodium formulation, showing significant anti-tumor activity in a bladder cancer mouse model. Two long-term survivors treated with oral PV-10 showed no gross bladder tumors at study end, a result not seen in control or anti-PD-1 groups. Oral PV-10 was the top-ranked treatment for efficacy, safety, and survival benefit, outperforming intravesical administration which showed toxicity at tested doses. The company plans to seek FDA approval for oral PV-10 human trials, targeting cancers with unmet needs like bladder, pancreatic, and glioblastoma.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Frasers Group PLC has withheld financial guidance for the upcoming year due to uncertainty around its takeover bids for Hugo Boss and Accent Group. The retailer's full-year adjusted profit before tax fell 4% to £538 million, impacted by asset impairm...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
